MIAMI—Heru Inc. announced yesterday that it has passed the clinical milestone of over 100,000 patient eyes that have been examined using its wearable technology since the company’s commercial launch a little over a year ago. Heru is a medical software company which delivers nine vision exams, supported with five reimbursable CPT medical billing codes, in a single, wearable AR/VR headset. The platform replaces several legacy diagnostic devices and exceeds traditional standards of care in usability, cost, size and portability, the company stated.

“We are thrilled to see the rapid adoption of the Heru platform,” said Mohamed Abou Shousha, MD, PhD, Heru’s founder, and CEO. “The momentum our technology is gaining in the vision care and health and wellness communities affirms our mission and further drives us to propel the continued development of our platform forward.”
Heru was born out of the University of Miami’s Bascom Palmer Eye Institute and developed in partnership with researchers, scientists and engineers following more than a decade of clinical study. Well known as an incubator of novel, disruptive technologies, Bascom Palmer’s core tenets of rigorous research and innovation have fed Heru’s rapid development of new testing modalities, allowing eyecare providers to easily fit a multitude of exams into their practice workflow.
“Heru’s technology is the epitome of what we aim to achieve in terms of clinical innovation,” said Eduardo C. Alfonso, MD, director of the Bascom Palmer Eye Institute and chairman of Heru’s Medical Advisory Board. An internationally renowned physician, surgeon, researcher, and professor, Dr. Alfonso leads the  institution whose research is aimed at identifying sight-threatening eye conditions and developing groundbreaking technology that challenges the status quo to diagnose, treat and manage those vision disorders.
Dr. Alfonso added, “From the technology’s infancy in the clinical research labs at Bascom Palmer to now examining over 100,000 eyes, I am exceptionally proud of what Heru has achieved. This platform is improving the quality of life for patients living with vision disorders around the world.”
Heru pioneered the first multi-modal wearable solution, which introduced several vision exams within a single platform. The platform’s dark adaptation and contrast sensitivity exams establish a market-leading AMD portfolio that may aid physicians in detecting subclinical AMD and monitoring disease progression. Future development includes therapeutic applications for personalized augmented vision correction.
Heru continues to expand its leadership executive team and board with high-profile appointments, as VMAIL reported in March 2022 and earlier this month. The company was a CES 2022 Innovation honoree. Dr. Shousha was a speaker at Vision Monday's 2021 Virtual VM Summit.